Jayasree Jonnadula, MD
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1578946323
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,138 of the $3,295 with a category attached, or 64.9%. 24 manufacturers reported payments, led by Medtronic at 48.1% of the total. Reporting peaked in 2023 at $1,854 and has fallen 89.7% since, to $191 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AL, where the typical reported total is $6,650.
Across 119 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$388
- Amgen$153
- Bayer$150
- Xeris Pharmaceuticals, Inc.$127
- Corcept Therapeutics$112
- plus $780 from 18 others
What the payments were for
- Travel & lodging$1,07333%
- Food & beverage$2,13865%
- Education$843%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $1,585 |
| Novo Nordisk | 24 | $388 |
| Amgen(2 entities) | 9 | $153 |
| Bayer | 10 | $150 |
| Xeris Pharmaceuticals, Inc. | 7 | $127 |
| Corcept Therapeutics | 6 | $112 |
| Amarin Pharma, Inc. | 6 | $108 |
| Lilly USA, LLC | 5 | $86 |
| Abbott | 4 | $79 |
| Insulet Corporation | 4 | $73 |
| Dexcom, Inc. | 4 | $62 |
| BETA Bionics, Inc. | 2 | $52 |
| IBSA Pharma Inc. | 3 | $51 |
| Grifols USA, LLC | 2 | $45 |
| Boston Scientific | 2 | $32 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Globus Medical | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,139
How this compares
$3,295 in reported general payments places this provider in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 424 | $617,154 |
| TrulicityDulaglutide | 327 | $416,245 |
| MounjaroTirzepatide | 194 | $241,509 |
| FarxigaDapagliflozin Propanediol | 214 | $235,285 |
| JardianceEmpagliflozin | 210 | $222,394 |
| RybelsusSemaglutide | 26 | $66,680 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $53,728 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $43,106 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 255 | $42,696 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $30,456 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 46 | $29,098 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $26,608 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $24,366 |
| Bydureon BciseExenatide Microspheres | 24 | $22,827 |
| Xigduo XrDapaglifloz Propaned/Metformin | 25 | $16,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $388 | $683,833450 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $86 | $657,754521 claims |
| AstraZenecaFarxiga | $16 | $235,285214 claims |
| Boehringer IngelheimJardiance | $31 | $222,394210 claims |
| IBSA Pharma Inc.Tirosint | $51 | $2,33315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Fernando OvalleBirmingham$15K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.